RxDoctor Payments Data

Jose Avila, MD

Emergency Medicine · Sarasota, FLNPI 1932183027

Payments from drug & device makers

$1,042in general payments, 2019–2025

Across 15 payments — averaging $69.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB, Inc.$490
  • Boston Scientific$216
  • Centinel Spine, LLC$155
  • EMD Serono, Inc.$53
  • Nalu Medical, Inc.$34
  • Novartis$30
  • plus $64 from 3 others

What the payments were for

  • Travel & lodging$33832%
  • Food & beverage$70468%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
UCB, Inc.2$490
Boston Scientific4$216
Centinel Spine, LLC1$155
EMD Serono, Inc.1$53
Nalu Medical, Inc.2$34
Novartis1$30
Pfizer1$29
Virtus Pharmaceuticals LLC2$24
Sunovion Pharmaceuticals Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,042 in reported general payments places this provider in the 90th percentile of 3,289 emergency medicine providers in Florida.

See all emergency medicine providers in Florida

Medicare billing

Part B allowed, 2024
$1,117,816
Medicare patients
1,827
Services billed
15,501

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban131$106,308
Humira(Cf)Adalimumab13$89,330
NuplazidPimavanserin Tartrate12$63,027
XareltoRivaroxaban56$35,149
JardianceEmpagliflozin38$26,796
MounjaroTirzepatide19$21,339
TrulicityDulaglutide13$16,015
Mesalamine12$8,695
Breo ElliptaFluticasone/Vilanterol14$5,883
BrilintaTicagrelor13$5,836
Cefdinir268$5,412
PaxlovidNirmatrelvir/Ritonavir43$4,288
Atorvastatin Calcium240$3,694
Levothyroxine Sodium312$3,273
Leflunomide12$3,163

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$29$110,596174 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,289 emergency medicine providers in Florida.

Other emergency medicine in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →